JPMorgan says Eli Lilly (LLY) announced positive results from orforglipron’s second Phase 3 trial in obesity. On efficacy, orforglipron showed weight loss of 9.6% at the highest dose, which is more in line with injectables and at the higher end of expectations, the analyst tells investors in a research note. In addition, orforglipron’s tolerability was largely in line with the ATTAIN-1 study and did not include any surprises, JPMorgan notes. The firm expects Lilly to file the data in obesity shortly, which could set up orforglipron for approval in obesity in mid-2026. Lilly remains one of JPMorgan’s top ideas with an Overweight rating. The stock in premarket trading is up 3% to $716.32.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Video: EchoStar surges after big AT&T wireless spectrum license buy
- Eli Lilly announces ATTAIN-2 trial met primary, secondary endpoints
- AstraZeneca and Eli Lilly’s Promising Phase 3 Study in Lung Cancer Treatment
- Eli Lilly’s Baricitinib Study: A Potential Game-Changer for Pediatric Alopecia Areata
- Eli Lilly’s Mirikizumab Study: A Potential Game-Changer for Ulcerative Colitis Treatment